#LCSM Chat Topic 5/3/18:  What Defines a “Quality” #LungCancer Treatment Center?  Thoughts from the Frontline

Our topic for the #LCSM Tweet Chat on Thursday, May 3rd (5 PM Pacific/8 PM Eastern) is “What Defines a “Quality” #LungCancer Treatment Center?  Thoughts from the Frontline.” The moderator for this chat is Dr. David Tom Cooke (@DavidCookeMD). Recently the Centers for Medicaid and Medicare Services (CMS) announced it would cover next-generation sequencing (NGS) for US patients with stage III or IV lung cancer when ordered by a physician and performed in a CLIA-certified laboratory.  This decision makes broad genomic testing to available to many more patients.  Having increased access to… Read More

#LCSM Chat Topic 3/22: Slicing the Pie–How Can Lung Cancer Patient Groups, Clinicians, and Researchers Best Work Together?

Lung cancer management has shifted from a broadly defined process to one increasingly recognized as narrow subgroups that have distinct patterns of cancer biology and optimal treatments.  The first patient group to splinter into a separate branch of management was the approximately 10% of people with EGFR mutation-positive NSCLC, and the treatment options for them continue to become deeper and more complex as we gain more active agents and struggle with enviable problems like the best sequencing and protection of the brain against metastatic spread. Other “driver mutations” such as ALK and… Read More

#LCSM Chat topic 3/8/2018: Cancer advocacy 101–patients & conferences

As cancer patients and caregivers transform into active cancer advocates, they may think about attending medical conferences.  On March 8, at 8 pm Eastern Time (5 pm PST), #LCSM Chat will discuss various aspects of cancer advocate participation in medical conferences. Some reasons for cancer advocates to attend medical conferences are to: Learn more about cancer and treatment options for cancer Get details about new research Meet the top doctors who treat their type of cancer Support an advocacy organization’s outreach booth Network with other advocates, as well as clinicians and researchers… Read More